Julie Baillet

Julie Baillet

Auto-generated profile, based on publicly available information

Julie Baillet

Department of Materials Science & Engineering, Stanford University

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2018 in Advanced Materials
Verified
Journal Article
Closed access
PDF file
JBJulie Baillet
Julie Baillet
VDValérie Desvergnes
Valérie Desvergnes
AHAladin Hamoud
Aladin Hamoud
LLLaurent Latxague
Laurent Latxague
PBPhilippe Barthelemy
Philippe Barthelemy

20 June 2023 in Advanced Healthcare Materials
Verified
Journal Article
Open access
BOBen S. Ou
Ben S. Ou
OSOlivia M. Saouaf
Olivia M. Saouaf
JYJerry Yan
Jerry Yan
TBTheodora U. J. Bruun
Theodora U. J. Bruun
JBJulie Baillet
Julie Baillet
EAEric A. Appel
Eric A. Appel
Most vaccines require several immunizations to induce robust immunity, and indeed, most SARS‐CoV‐2 vaccines require an initial two‐shot regimen followed by several boosters to maintain efficacy. Such a complex series of immunizations unfortunately increases the cost and complexity of populations‐scale vaccination and reduces overall compliance and vaccination rate. In a rapidly evolving pandemic affected by the spread of immune‐escaping variants, there is an urgent need to develop vaccines capable of providing robust and durable immunity. In this work, a single immunization SARS‐CoV‐2 subunit vaccine is developed that can rapidly generate potent, broad, and durable humoral immunity. Injectable polymer–nanoparticle (PNP) hydrogels are leveraged as a depot technology for the sustained delivery of a nanoparticle antigen (RND‐NP) displaying multiple copies of the SARS‐CoV‐2 receptor‐binding domain (RBD) and potent adjuvants including CpG and 3M‐052. Compared to a clinically relevant prime‐boost regimen with soluble vaccines formulated with CpG/alum or 3M‐052/alum adjuvants, PNP hydrogel vaccines more rapidly generated higher, broader, and more durable antibody responses. Additionally, these single‐immunization hydrogel‐based vaccines elicit potent and consistent neutralizing responses. Overall, it is shown that PNP hydrogels elicit improved anti‐COVID immune responses with only a single administration, demonstrating their potential as critical technologies to enhance overall pandemic readiness.

11 April 2025 in Science Advances
Verified
Journal Article
Open access
EMEmily L. Meany
Emily L. Meany
JKJohn H. Klich
John H. Klich
CJCarolyn K. Jons
Carolyn K. Jons
TMTianyang Mao
Tianyang Mao
NCNamit Chaudhary
Namit Chaudhary
EAEric Appel
Eric Appel
Messenger RNA (mRNA) delivered in lipid nanoparticles (LNPs) rose to the forefront of vaccine candidates during the COVID-19 pandemic due to scalability, adaptability, and potency. Yet, there remain critical areas for improvements of these vaccines in durability and breadth of humoral responses. In this work, we explore a modular strategy to target mRNA/LNPs to antigen-presenting cells with an injectable polymer-nanoparticle (PNP) hydrogel technology, which recruits key immune cells and forms an immunological niche in vivo. We characterize this niche on a single-cell level and find it is highly tunable through incorporation of adjuvants like MPLAs and 3M-052. Delivering commercially available severe acute respiratory syndrome coronavirus 2 mRNA vaccines in PNP hydrogels improves the durability and quality of germinal center reactions, and the magnitude, breadth, and durability of humoral responses. The tunable immune niche formed within PNP hydrogels effectively skews immune responses based on encapsulated adjuvants, creating opportunities to precisely modulate mRNA/LNP vaccines for various indications from infectious diseases to cancers.

9 August 2024 in Science Advances
Verified
Journal Article
Open access
BOBen S. Ou
Ben S. Ou
JBJulie Baillet
Julie Baillet
MIMaria V. Filsinger Interrante
Maria V. Filsinger Interrante
JAJulia Z. Adamska
Julia Z. Adamska
XZXueting Zhou
Xueting Zhou
EAEric A. Appel
Eric A. Appel
Over the past few decades, the development of potent and safe immune-activating adjuvant technologies has become the heart of intensive research in the constant fight against highly mutative and immune evasive viruses such as influenza, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and human immunodeficiency virus (HIV). Herein, we developed a highly modular saponin-based nanoparticle platform incorporating Toll-like receptor agonists (TLRas) including TLR1/2a, TLR4a, and TLR7/8a adjuvants and their mixtures. These various TLRa–saponin nanoparticle adjuvant constructs induce unique acute cytokine and immune-signaling profiles, leading to specific T helper responses that could be of interest depending on the target disease for prevention. In a murine vaccine study, the adjuvants greatly improved the potency, durability, breadth, and neutralization of both COVID-19 and HIV vaccine candidates, suggesting the potential broad application of these adjuvant constructs to a range of different antigens. Overall, this work demonstrates a modular TLRa-SNP adjuvant platform that could improve the design of vaccines and affect modern vaccine development.

28 September 2016 in Gels
Verified
Journal Article
Open access
PDF file
LLLaurent Latxague
Laurent Latxague
AGAlexandra gaubert
Alexandra gaubert
DMDavid Maleville
David Maleville
JBJulie Baillet
Julie Baillet
MRMichael A. Ramin
Michael A. Ramin
PBPhilippe Barthelemy
Philippe Barthelemy
A new bolaamphiphile analog featuring carbamate moieties was synthesized in six steps starting from thymidine. The amphiphile structure exhibits nucleoside-sugar polar heads attached to a hydrophobic spacer via carbamate (urethane) functions. This molecular structure, which possesses additional H-bonding capabilities, induces the stabilization of low-molecular-weight gels (LMWGs) in water. The rheological studies revealed that the new bolaamphiphile 7 stabilizes thixotropic hydrogels with a high elastic modulus (G′ > 50 kPa).

14 February 2020 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
JBJulie Baillet
Julie Baillet
AGAlexandra Gaubert
Alexandra Gaubert
DBDario M. Bassani
Dario M. Bassani
JVJulien Verget
Julien Verget
LLLaurent Latxague
Laurent Latxague
PBPhilippe Barthelemy
Philippe Barthelemy
Light-sensitive Low Molecular Weight Gelators (LMWGs) derived from glyconucleoside bolaamphiphiles containing a stilbene unit displayed gelation abilities in hydroalcoholic mixtures. These materials showed a gel–sol transition under UV irradiation thanks to E–Z isomerization of stilbene and could find potential applications as drug delivery systems.